Please assess the completion status of the following clinical trial:

Trial Title: Escalated Dose of Irinotecan in mCRC

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. 20 y/o ≦ Age ≦ 80y/o~2. Either metachronous or synchronous mCRC can be enrolled~3. Female patients need not ready to be pregnant or breastfeeding~4. No major underlying diseases (such as cardiovascular, cerebrovascular, malignant hypertension, kidney, liver and other major diseases)~5. mCRC be proven by pathologists or radiologists~6. Subjects are willing to sign an inform consent form~Exclusion Criteria:~* Patients who do not meet the including criteria or unwilling to participate

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- UGT1A1 genotyping (6,6) (Type: EXPERIMENTAL): The investigators will escalate the dosage of irinotecan from 180mg/m2 to 260 mg/m2
- UGTA1T1 genotyping (6,7) (Type: EXPERIMENTAL): The investigators will escalate the dosage of irinotecan from 180mg/m2 to 240 mg/m2
- UGTA1T1 genotyping (7,7) (Type: EXPERIMENTAL): The investigators will escalate the dosage of irinotecan from 120mg/m2 to 180 mg/m2
- UGT1A1 non-genotyping (Type: EXPERIMENTAL): The investigators will maintain the dosage of irinotecan by 180mg/m2

Based on this trial design, predict the completion outcome and termination type (if applicable).